PD-L1 Decoy - AB Biosciences
Alternative Names: PD-L1 DecoyLatest Information Update: 13 Feb 2024
At a glance
- Originator AB Biosciences
- Class Antineoplastics; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cachexia
Most Recent Events
- 05 Dec 2023 Preclinical trials in Cachexia in USA (Parenteral) before December 2023 (AB Biosciences pipeline, December 2023)